LongBio Pharma (Suzhou) Co., Ltd. (SEHK: 1779)
Health Care · Biotechnology · CN
HK$98.00
-3.64% today · -25.6% 1Y
LongBio Pharma (Suzhou) Co., Ltd. (SEHK: 1779) operates in the Biotechnology industry within the Health Care sector. The company is valued at $926.52M and employs 85 people.
Over the last twelve months the share price has lost 25.6%, trading between 72.65 and 165.90.
Tweenvest scores LongBio Pharma (Suzhou) Co., Ltd. across four factors: quality 44/100, value 74/100. Its strongest factor is value.
1779 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $926.52M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.50
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$165.90
- 52-week low
- HK$72.65
- Avg volume (3M)
- —
- Shares outstanding
- 74.19M
- Employees
- 85
- Next earnings
- —
About LongBio Pharma (Suzhou) Co., Ltd.
Longbio Pharma (Suzhou) Co., Ltd. operates as a clinical-stage biotechnology company. It focuses on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. The company was founded by Heng Liu and Nai-Chau Sun on October 26, 2020 and is headquartered Suzhou, China.
- ISIN
- CNE100007NF2
- Founded
- 2020
- Listed since
- Jun 5, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai Haohai Biological Technology Co., Ltd.SEHK: 6826 | $943.26M | HK$16.11 | +0.25% |
| Kura Oncology, Inc.NasdaqGS: KURA | $942.98M | $10.60 | +0.76% |
| Ascletis Pharma Inc.SEHK: 1672 | $936.85M | HK$6.96 | -14.23% |
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $932.34M | ₩25,350.00 | -12.13% |
| MoonLake ImmunotherapeuticsNasdaqCM: MLTX | $920.85M | $10.82 | +2.27% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $916.81M | $49.08 | +0.74% |
| Jade Biosciences, Inc.NasdaqCM: JBIO | $915.17M | $14.39 | +1.91% |
| Odyssey Therapeutics, Inc.NasdaqCM: ODTX | $910.45M | $19.00 | -8.32% |
Figures last refreshed Oct 11, 2026.